Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : American House Dust Mite Extract,European House Dust Mite Extract
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : GeneScience Pharmaceuticals Co Ltd
Deal Size : $209.7 million
Deal Type : Partnership
ALK and GenSci Partner to Expand the AIT Market in China
Details : GenSci is granted exclusive rights to ALK’s house dust mite AIT products, including Acarizax SLIT-tablet, in China.
Product Name : Acarizax
Product Type : Undisclosed
Upfront Cash : $38.7 million
September 17, 2025
Lead Product(s) : American House Dust Mite Extract,European House Dust Mite Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : GeneScience Pharmaceuticals Co Ltd
Deal Size : $209.7 million
Deal Type : Partnership
Lead Product(s) : House Dust Mite
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HDM SLIT-Tablet Studied For Allergy Treatment In Chinese Patients Aged 12–65
Details : House Dust Mite is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 11, 2025
Lead Product(s) : House Dust Mite
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allergen Extract, White Birch
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Itulatek Approved for Treatment of Children and Adolescents in Canada
Details : Itulatek is a sublingual immunotherapy tablet made from a standard allergen extract of white birch and is the first in the class of SLIT for treatment of children and adolescents aged 5 to 17.
Product Name : Itulatek
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Allergen Extract, White Birch
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ACARIZAX® Approved in Canada for Treatment of Young Children
Details : Acarizax is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae. It is being indicated for the treatment of house dust mite allergy.
Product Name : Acarizax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves ODACTRA for the Treatment of House Dust Mite Allergy in Young Children
Details : Odactra is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae. It is indicated for the treatment of house dust mite allergy.
Product Name : Odactra
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : Dermatophagoides Farinae Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arachis Hypogaea Allergen Extract
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results Advance Peanut Tablet to Phase II Development
Details : ALK Abello AS is developing sublingual immunotherapy (‘SLIT’) tablets and it is under phase 1/2 clinical development for the treatment of Peanut Allergy.
Product Name : Peanut SLIT-tablet
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : Arachis Hypogaea Allergen Extract
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ACARIZAX® Approved in Europe for Treatment of Young Children
Details : Acarizax is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae. It is being indicated for the treatment of house dust mite allergy.
Product Name : Acarizax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ALK Licenses Rights to Neffy®, Adrenaline Nasal Spray for Anaphylaxis Treatment
Details : The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, for emergency treatment of allergic reactions (anaphylaxis).
Product Name : Neffy
Product Type : Hormone
Upfront Cash : Undisclosed
November 09, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Birch Pollen Extract
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ALK's European Reg Application for ITULAZAX® for Paediatric Indication Accepted for Review
Details : ITULAZAX is a sublingual immunotherapy tablet of allergen extract for immunotherapy to treat pollen-induced allergic rhinitis and/or conjunctivitis.
Product Name : Itulazax
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Birch Pollen Extract
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ALK's Application for House Dust Mite SLIT-Tablet in Children Accepted for Review
Details : Acarizax is a standardised allergen extract from house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae, for the treatment of house dust mite allergy.
Product Name : Acarizax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : House Dust Mite Allergen Extract,Dermatophagoides Pteronyssinus Extract
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable